Michael R Mcdevitt

List of Publications by Year
in descending order

Version: 2024-02-01

39 papers	3,112 citations	279798 23 h-index	302126 39 g-index
42 all docs	42 docs citations	42 times ranked	3958 citing authors

#	Article	IF	Citations
1	Targeted Î± particle immunotherapy for myeloid leukemia. Blood, 2002, 100, 1233-1239.	1.4	430
2	Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes. Journal of Nuclear Medicine, 2007, 48, 1180-1189.	5.0	414
3	Paradoxical glomerular filtration of carbon nanotubes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12369-12374.	7.1	372
4	Design and synthesis of 225Ac radioimmunopharmaceuticals. Applied Radiation and Isotopes, 2002, 57, 841-847.	1.5	187
5	Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nature Reviews Clinical Oncology, 2010, 7, 266-276.	27.6	173
6	PET Imaging of Soluble Yttrium-86-Labeled Carbon Nanotubes in Mice. PLoS ONE, 2007, 2, e907.	2.5	169
7	Targeted alpha particle immunotherapy for myeloid leukemia. Blood, 2002, 100, 1233-9.	1.4	143
8	Î±-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studiesâ€"Part 1. Journal of Nuclear Medicine, 2018, 59, 878-884.	5.0	131
9	Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. International Journal of Nanomedicine, 2010, 5, 783.	6.7	117
10	Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nature Nanotechnology, 2013, 8, 763-771.	31.5	99
11	Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Science Translational Medicine, 2016, 8, 331ra39.	12.4	88
12	Synthesis and Biodistribution of Oligonucleotide-Functionalized, Tumor-Targetable Carbon Nanotubes. Nano Letters, 2008, 8, 4221-4228.	9.1	81
13	Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. Journal of Nuclear Medicine, 2004, 45, 129-37.	5.0	79
14	Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with ²²⁵Ac for Î±-Particle Radioimmunotherapy of Cancer. Journal of Nuclear Medicine, 2014, 55, 1492-1498.	5.0	73
15	Î±-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studiesâ€"Part 2. Journal of Nuclear Medicine, 2018, 59, 1020-1027.	5.0	72
16	Targeted and Nontargeted Î±-Particle Therapies. Annual Review of Biomedical Engineering, 2018, 20, 73-93.	12.3	46
17	Deconvoluting hepatic processing of carbon nanotubes. Nature Communications, 2016, 7, 12343.	12.8	42
18	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications, 2018, 9, 1629.	12.8	37

#	Article	IF	Citations
19	Deploying RNA and DNA with Functionalized Carbon Nanotubes. Journal of Physical Chemistry C, 2013, 117, 5982-5992.	3.1	35
20	Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled Î±-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles. Biomaterials, 2020, 241, 119858.	11.4	35
21	Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma. Journal of Nuclear Medicine, 2016, 57, 1576-1582.	5.0	30
22	Advances in the clinical translation of nanotechnology. Current Opinion in Biotechnology, 2017, 46, 66-73.	6.6	30
23	Alpha radioimmunotherapy using ²²⁵Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics, 2020, 10, 11359-11375.	10.0	26
24	Remodeling the Vascular Microenvironment of Glioblastoma with Î±-Particles. Journal of Nuclear Medicine, 2016, 57, 1771-1777.	5.0	25
25	Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes. International Journal of Nanomedicine, 2014, 9, 4245.	6.7	21
26	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clinical Cancer Research, 2019, 25, 881-891.	7.0	21
27	A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. Clinical Cancer Research, 2021, 27, 532-541.	7.0	19
28	Carbon nanotubes exhibit fibrillar pharmacology in primates. PLoS ONE, 2017, 12, e0183902.	2.5	18
29	In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget, 2017, 8, 65917-65931.	1.8	17
30	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted Î±-particle therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15172-15181.	7.1	16
31	A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with Î± Particle-Emitting Ultrasmall Silica Nanoparticles. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 459-473.	1.0	13
32	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060.	7.0	13
33	Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 1790-1790.	1.4	12
34	Fibrillar pharmacology of functionalized nanocellulose. Scientific Reports, 2021, 11, 157.	3.3	8
35	Fibrillous Carbon Nanotube: An Unexpected Journey. Critical Reviews in Oncogenesis, 2014, 19, 261-268.	0.4	7
36	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate Chemistry, 2021, 32, 649-654.	3.6	6

#	Article	IF	Citations
37	[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 783-785.	6.4	4
38	The effects of amine-modified single-walled carbon nanotubes on the mouse microbiota. International Journal of Nanomedicine, 2018, Volume 13, 5275-5286.	6.7	2
39	Dialytic Separation of Bundled, Functionalized Carbon Nanotubes from Carbonaceous Impurities. Crystals, 2014, 4, 450-465.	2.2	1